SAMANTHA MOLLMAN: Open Payments
NPI 1043612609 · BISMARCK, ND. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$691 in 31 payments from 14 companies in 2025. Trend: 2023 $171 · 2024 $358 · 2025 $691
Food & beverage: $691
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $172 |
| GENZYME CORPORATION | 2 | $97 |
| Eisai Inc. | 2 | $70 |
| GlaxoSmithKline, LLC. | 4 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Novartis Pharmaceuticals Corporation | 2 | $47 |
| BioCryst US Sales Co., LLC | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| CSL Behring | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: DUPIXENT, Leqembi, TEZSPIRE, NUCALA, FASENRA, ORLADEYO, REXULTI, Haegarda.
Industry payments across ND — which companies pay providers there.
